News zum Sektor Gesundheit aus Asien

 

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a high-priority biothreat to national health security. The order exercises the first of several procurement and related options under the contract, with initial funding of $119 million and multiyear options for a total of up to $482 million. Other projects under the contract include establishing a U.S. drug product manufacturing site for Fetroja, advancing Fetroja for the treatment of infections caused by high-priority biothreat pathogens and exp...

Hong Kong Exchanges and Clearing (HKEX) will add 10 companies – including autonomous-driving firms Pony AI and WeRide – to its Tech 100 Index as part of a quarterly reshuffle that increases the benchmark's exposure to artificial intelligence and other emerging technologies. Other additions include AI drug-discovery specialist Insilico Medicine, printed-circuit-board maker Victory Giant Technology, enterprise AI company Beijing Haizhi Technology and AI data-intelligence provider Mininglamp......

DUALITYBIO-B (09606.HK) announced its interim results for the period ended end-June 2026. Revenue was RMB219 million, down 82.2% YoY. Loss narrowed to RMB918 million from a loss of RMB2.074 billion in the corresponding period last year. LPS was RMB10.2. No dividend was declared. (da)~AASTOCKS Financial NewsWebsite: www.aastocks.......

HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting......

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is The post FDA to review Kowa Pharmaceuticals' NDA for glaucoma eye drop K-911 appeared first on Pharmaceutical Business review....

HKEX (00388.HK) announced the results of the September quarterly review of the HKEX Tech 100 Index. The quarterly adjustment adopted the optimized compilation methodology announced earlier this month.The Tech 100 Index will add WERIDE-W (00800.HK), PONY-W (02026.HK), VGT (02476.HK), HAIZHI TECH GP (02706.HK), MININGLAMP-W (02718......

G Sachs issued a research report saying that INNOCARE (09969.HK)'s product sales in the second quarter rose 37% YoY, broadly in line with expectations, benefiting from continued strong growth of its core product orelabrutinib, as well as initial contributions from newly launched tafasitamab (CD19) and Zurletrectinib (pan-TRK).G ......

Herbalife, Honda Motor, Marathon, Halozyme and Genworth have been highlighted in this Screen of The Week article....

CICC issued a report saying that WUXI BIO (02269.HK) saw improved profitability, while its project pipeline and complex molecule business continued to expand. Its revenue for the first half of the year was RMB11.787 billion, up 18.4% YoY, or up 23.4% YoY at constant exchange rates. Gross margin rose 3.5 ppts YoY to 46.2%. Net pr......

China Merchants Securities (HK) issued a research report stating that INNOVENT BIO (01801.HK)'s total revenue in the first half of the year increased 56.7% YoY, in line with expectations. The SG&A expense ratio fell by 4 ppts, while the R&D expense ratio rose by 2.6 ppts, reflecting stringent control over overall selling and adm......

China Life Insurance, the country's largest life insurer, has posted record highs in its first-half results, and says it will scale up investments in technology-related sectors while seeking to become a long-term partner for innovative enterprises. The Shanghai- and Hong Kong-listed insurer recorded revenue of 434.3 billion yuan (US$64.6 billion), up 81.5 per cent year on year, according to interim results released on Thursday. Net profit surged more than 228 per cent to 134.5 billion yuan. The......

GUSHENGTANG (02273.HK) announced its interim results at noon today. Its share price leapfrogged in the afternoon session, breaking above multiple MAs in one move. The stock peaked at HKD30.22, hitting a more-than-one-month high. It last posted at HKD29.88, up 11.16%, with volume surging to 1.5027 million shares, involving turnov......

Zulassungsantrag für „K-911″ zur Behandlung von Patienten mit Glaukom und okulärer Hypertonie von der U.S. Food and Drug Administration zur Prüfung angenommen...

Xuefeng Yu, Chairman & CEO of CanSino Biologics, discusses the Chinese vaccine maker's first-half results and clinical pipeline. He speaks exclusively on "Bloomberg: The China Show." (Source: Bloomberg)...

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises......

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively......

LIVZON PHARMA (01513.HK) announced that Livzon Mab, its controlling subsidiary, has received a Drug Registration Certificate approved and issued by the National Medical Products Administration. Laikangqita Monoclonal Antibody Injection (subcutaneous injection) (Libeitan) has met the relevant requirements for drug registration an......

CSPC PHARMA (01093.HK) announced that the SYH2092 injection developed by the group has been approved by the National Medical Products Administration of China to commence clinical trials in China.The product is an amylin receptor agonist. By optimizing agonist activity, the product is expected to improve efficacy while maintainin......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...